Related references
Note: Only part of the references are listed.Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7
Jiro Kikuchi et al.
LEUKEMIA (2020)
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement
Wilson I. Gonsalves et al.
BONE MARROW TRANSPLANTATION (2019)
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Brian A. Walker et al.
LEUKEMIA (2019)
Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability
Ankit K. Dutta et al.
LEUKEMIA (2019)
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma
Anjan Thakurta et al.
BLOOD (2019)
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
John R. Jones et al.
HAEMATOLOGICA (2019)
EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation
Laurie Herviou et al.
LEUKEMIA (2019)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?
Giovanni Barosi et al.
LEUKEMIA (2019)
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
Susan Branford et al.
LEUKEMIA (2019)
PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage
Jinfang Zhang et al.
CANCER DISCOVERY (2019)
Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells
Hiroyuki Yamazaki et al.
SCIENTIFIC REPORTS (2019)
Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation
Tadahiko Matsumoto et al.
SCIENTIFIC REPORTS (2019)
Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies
Ai-Lin Zhao et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Mutational processes contributing to the development of multiple myeloma
Phuc H. Hoang et al.
BLOOD CANCER JOURNAL (2019)
Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma
Alexander M. Lesokhin et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
Francesco Maura et al.
NATURE COMMUNICATIONS (2019)
Evolution of Cancer Progression in the Context of Darwinism
Lukas Lacina et al.
ANTICANCER RESEARCH (2019)
The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
David Vrabel et al.
BLOOD REVIEWS (2019)
A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma
Shin-ichi Fuchida et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H. Jackson et al.
LANCET ONCOLOGY (2019)
MMSET I acts as an oncoprotein and regulates GLO1 expression in t (4;14) multiple myeloma cells
Zhigang Xie et al.
LEUKEMIA (2019)
Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
Katarina K. Jovanovic et al.
FRONTIERS IN ONCOLOGY (2019)
Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop
Tina Bagratuni et al.
SCIENTIFIC REPORTS (2019)
Impact of acquired del(17p) in multiple myeloma
Arjun Lakshman et al.
BLOOD ADVANCES (2019)
Smoldering Multiple Myeloma To Treat or Not to Treat
Prashant Kapoor et al.
CANCER JOURNAL (2019)
Immunotherapy in myeloma: how far have we come?
Laurens E. Franssen et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s
Joshua Kellner et al.
JCI INSIGHT (2019)
Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma
A. Lagana et al.
LEUKEMIA (2018)
Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation
R. Chakraborty et al.
LEUKEMIA (2018)
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines
F. Maura et al.
LEUKEMIA (2018)
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
V. Shah et al.
LEUKEMIA (2018)
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
C. S. Chim et al.
LEUKEMIA (2018)
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Brian A. Walker et al.
BLOOD (2018)
The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma
Leo Rasche et al.
BLOOD (2018)
Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide
Jiro Kikuchi et al.
CANCER RESEARCH (2018)
From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells
Niels van Nieuwenhuijzen et al.
CANCER RESEARCH (2018)
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
Marjorie Pick et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Immunopathogenesis and immunotherapy of multiple myeloma
Hideto Tamura
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
Niccolo Bolli et al.
LEUKEMIA (2018)
Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling
Masafumi Taniwaki et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2018)
Genomic patterns of progression in smoldering multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2018)
Maintenance Treatment and Survival in Patients With Myeloma A Systematic Review and Network Meta-analysis
Francesca Gay et al.
JAMA ONCOLOGY (2018)
Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity
Yuki Fujiwara et al.
CANCER RESEARCH (2018)
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
Guy Ledergor et al.
NATURE MEDICINE (2018)
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project
Saad Z. Usmani et al.
BLOOD CANCER JOURNAL (2018)
Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance
Nicholas Nikesitch et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2018)
Trends in overall survival and costs of multiple myeloma, 2000-2014
R. Fonseca et al.
LEUKEMIA (2017)
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
Sharmilan Thanendrarajan et al.
HAEMATOLOGICA (2017)
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma
Aneta Mikulasova et al.
HAEMATOLOGICA (2017)
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
Philip L. McCarthy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Understanding cancer from the stem cells up
Christopher A. Eide et al.
NATURE MEDICINE (2017)
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
L. Rasche et al.
NATURE COMMUNICATIONS (2017)
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
M. Chin et al.
BLOOD CANCER JOURNAL (2017)
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
M. Binder et al.
BLOOD CANCER JOURNAL (2017)
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
Sharmilan Thanendrarajan et al.
HAEMATOLOGICA (2017)
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma
Aneta Mikulasova et al.
HAEMATOLOGICA (2017)
Evolutionary biology of high-risk multiple myeloma
Charlotte Pawlyn et al.
NATURE REVIEWS CANCER (2017)
Somatic mosaicism in chronic myeloid leukemia in remission
Kinuko Mitani et al.
BLOOD (2016)
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
Niels Weinhold et al.
BLOOD (2016)
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
K. Martin Kortum et al.
BLOOD (2016)
Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition
Marc S. Raab et al.
BLOOD (2016)
Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma
Masaki Ri
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma
Yusuke Furukawa et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
Maryam Pourabdollah et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer
Dawid Walerych et al.
NATURE CELL BIOLOGY (2016)
Identification of neutral tumor evolution across cancer types
Marc J. Williams et al.
NATURE GENETICS (2016)
Differential effects of lenalidomide during plasma cell differentiation
Michel Jourdan et al.
ONCOTARGET (2016)
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
Marie-Lorraine Chretien et al.
BLOOD (2015)
Molecular pathogenesis of multiple myeloma
Yusuke Furukawa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project
Megumi Hori et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma
Jiro Kikuchi et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
Brian A. Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
B. Paiva et al.
LEUKEMIA (2015)
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
Brian A. Walker et al.
NATURE COMMUNICATIONS (2015)
Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma
S. Ozaki et al.
BLOOD CANCER JOURNAL (2015)
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns
Ingrid Cifola et al.
ONCOTARGET (2015)
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
Charlotte Pawlyn et al.
BLOOD (2015)
Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma
Isabella C. Glitza et al.
LEUKEMIA & LYMPHOMA (2015)
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Yuan Xiao Zhu et al.
BLOOD (2014)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
B. A. Walker et al.
LEUKEMIA (2014)
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
L. Melchor et al.
LEUKEMIA (2014)
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
M. Affer et al.
LEUKEMIA (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
Aristeidis Chaidos et al.
BLOOD (2013)
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells
Brian A. Walker et al.
BLOOD (2013)
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
Chungyee Leung-Hagesteijn et al.
CANCER CELL (2013)
The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma
Benjamin Hebraud et al.
CLINICAL CANCER RESEARCH (2013)
Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome
Katia Todoerti et al.
CLINICAL CANCER RESEARCH (2013)
Exome sequencing in tracking clonal evolution in multiple myeloma following therapy
N. Weston-Bell et al.
LEUKEMIA (2013)
Minor clone provides a reservoir for relapse in multiple myeloma
F. Magrangeas et al.
LEUKEMIA (2013)
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
H. Tamura et al.
LEUKEMIA (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma
Zhigang Xie et al.
ONCOTARGET (2013)
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma
Brian A. Walker et al.
BLOOD (2012)
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
Jan B. Egan et al.
BLOOD (2012)
Clonal competition with alternating dominance in multiple myeloma
Jonathan J. Keats et al.
BLOOD (2012)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
Laurence Lode et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
A model of mutation appropriate to estimate the number of electrophoretically detectable alleles in a finite population
Tomoko Ohta et al.
GENETICS RESEARCH (2007)
Share Paper
